Glaucoma Treatment Thresholds: Research Challenges the 22 mmHg Rule
Current research indicates a continuous link between glaucoma risk and intraocular pressure (IOP), challenging the long-held clinical practice of initiating treatment only when IOP exceeds 22 mmHg. A study published in JAMA Ophthalmology suggests that glaucoma treatment is often initiated at an IOP of 22 mmHg, but risk consistently increases even at lower levels.
Evolving Understanding of IOP and Glaucoma
For decades, a threshold of 22 mmHg has guided clinicians in deciding when to start or escalate glaucoma therapy. Although, a growing body of evidence demonstrates that the relationship between IOP and glaucoma isn’t a simple on/off switch. Instead, glaucoma risk increases incrementally with rising IOP, even below 22 mmHg. This challenges the notion of a definitive IOP cutoff for treatment decisions.
Study Findings and Data Analysis
Researchers analyzed electronic health record data from seven academic centers within the Sight Outcomes Research Collaborative database, encompassing 184,504 eyes from 94,232 patients. The analysis focused on identifying instances where patients received IOP-lowering treatment – defined as a new prescription within one week of a visit, laser treatment within four weeks, or glaucoma surgery within eight weeks – and correlating these treatments with different IOP levels.
The study revealed a noticeable increase in the likelihood of treatment initiation as IOP rose from 17 mmHg to 21 mmHg. However, a more substantial increase in treatment odds occurred at 22 mmHg, suggesting adherence to the historical IOP cutoff.
Implications for Clinical Practice
The findings highlight a potential disconnect between current clinical practice and the latest research. The continued reliance on a 22 mmHg threshold may lead to delayed treatment for some patients who are already at increased risk. Researchers suggest that implementing clinical decision support systems could help reduce reliance on heuristics and improve treatment decisions in ophthalmology.
Future Directions
The authors emphasize the need for user-focused clinical decision support systems to aid clinicians in making informed treatment choices. These systems could help move beyond the traditional 22 mmHg cutoff and incorporate a more nuanced understanding of the continuous relationship between IOP and glaucoma risk. This could lead to earlier intervention and potentially better outcomes for patients.